

Vectura Group PLC

09:06 12 Jan 2021

Vectura hikes guidance after approval of a generic Advair and CDMO wins

Vectura Group PLC (LON:VEC) said sales and profits for 2020 will be better than the market expects, after the approval of a generic version of asthma drug Advair in December.

This US regulatory approval led to an US\$11m milestone payment from partner Hikma.

Moreover, the drug formulation specialist said it has won 18 contracts under its inhalation contract development and manufacturing organization (CDMO) strategy, with roughly £3m of revenue from this new business being recognised in the second half of the year.

Management said they expect CDMO revenue to more than treble in 2021, while also anticipating £5-7m of operating expenditure savings from a planned site closure in Switzerland, offset by some "low single-digit millions" of exceptional cash costs from the transition towards a development services model.


Vectura said it closed the year with cash and equivalents of roughly £79m, versus £81.9m at the half year.

A previously announced US\$200m patent litigation win against GlaxoSmithKline is expected to be mostly paid by the end of this month and subject to 10% tax.

Price: 112

Market Cap: £667.48 m

1 Year Share Price Graph



February 2020 August 2020 February 2021

Share Information

Code: VEC

Listing: AIM

52 week **High** **Low**
131.6 59.1

Sector: Pharma & Biotech

Website: www.vectura.co.uk

Company Synopsis:

Vectura Group plc, (Vectura) along with its subsidiaries, is principally engaged in the research and development of therapeutic products and drug delivery systems for human use. The Company is focused on the development of inhaled pharmaceuticals. It has eight marketed products and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to pharmaceutical companies.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.